tTF-NGR Randomized Study - STS

In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade \>/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the re

Trial Details

NCT ID
NCT05597917
Phase
PHASE3
Sponsor
Universität Münster
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Trabectedin
  • tTF-NGR
Locations (sample)
  • Augsburg, Germany|48.37154,10.89851
  • Bad Saarow, Germany|52.28333,14.06667
  • Berlin, Germany|52.52437,13.41053
  • Dresden, Germany|51.05089,13.73832
  • Frankfurt, Germany|49.68333,10.53333

Key Eligibility Criteria

  • Patients of all genders (female, male, diverse), with no restriction regarding ethnic or religious background age 18 - 75 years.
  • Patients with advanced or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy (or anthracycline-containing …
  • Patients must have histological evidence of high-grade advanced unresectable or metastatic soft tissue sarcoma (grade 2 - 3) according to the FNCLC…
  • Dedifferentiated liposarcoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →